Madam,
We read with interest the recently published review article by Patel et al. titled “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.”[1] Tanezumab is under investigation for the treatment of osteoarthritis pain and chronic low back pain by Pfizer Inc. and Eli Lilly & Company. As Pfizer or Lilly were not involved or consulted regarding the content of this article, we would like to point out that the molecular formula of tanezumab presented in Figure 1 is incorrect. For a more accurate representation of the structure of tanezumab, we refer readers to an article by La Porte et al.[2]
—On behalf of the tanezumab development team.
Financial support and sponsorship
Editorial support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Eli Lilly & Co and Pfizer.
Conflicts of interest
Leslie Tive is a full-time employee of, and own stock and/or stock options in, Pfizer Inc. David Shelton is a consultant for, and owns stock in, Pfizer Inc. Lars Viktrup is a full-time employee of, and owns stock and/or stock options in, Eli Lilly & Company.
References
- 1.Patel MK, Kaye AD, Urman RD. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018;34:111–6. doi: 10.4103/joacp.JOACP_389_15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.La Porte SL, Eigenbrot C, Ultsch M, Ho WH, Foletti D, Forgie A, et al. Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized fab-antigen complexes. MAbs. 2014;6:1059–68. doi: 10.4161/mabs.28677. [DOI] [PMC free article] [PubMed] [Google Scholar]